🔥Telegram İfşa

Estudio que evalua la viabilidad de un programa de reciclaje de PVC para residuos urológicos. Participación del INCMNSZ Horst Emanuel Lagos Beitz y cols.

* * * LA CAMISETA * * * Clínica de Andrología del INCMNSZ; la primera en el sector público de México ¡Ya puedes consultar La Camiseta del 30 de junio! incmnsz.mx/opencms/Camise… Descarga: incmnsz.mx/2025/LaCamiset…

Clínica de Andrología #UroINCMNSZ

It's been a great honor to be part of the Latin America reviewers of National Comprehensive Cancer Network (NCCN) Guidelines on Kidney Cancer framework 2025 for the second year in a row LARCG Diego Abreu Stenio Zequi Martín Angel

Urocápsula SMU #UroINCMNSZ

Concurso de Estudios Diagnósticos, Julio 2025 SMU #UroINCMNSZ

Prostate cancer cases are expected to double worldwide by 2040 to nearly 3 million per year. Advanced imaging and robotic surgery are transforming diagnosis and treatment, improving precision and patient outcomes. brnw.ch/21wVx6f

Renal-cell carcinoma (RCC) diagnosis has shifted toward earlier stages. In this paper we analyzed 807 surgically treated RCC patients in Mexico (1980-2024) to evaluate stage migration patterns.

In 807 surgically treated RCC patients in Mexico (1980–2024), stage I cases rose (29.9→52.9%) while stage III–IV declined, with survival improving from 85.7→96.3%. Gains extend beyond early detection, highlighting advances in comprehensive RCC management.

Todos en la Sociedad Mexicana de Urología apoyamos y le deseamos éxito a nuestro #ResidenteSMU en el Concurso de Residentes Intersociedades CAU. 👏🏻👏🏻 👨🏻‍⚕️ Rodrigo Escalante Armenta 🎓 Tema: “Manejo de Masas Renales” 🥊 México vs Perú Los invitamos a conectarse aquí:

Estudio que evaluó la asociación entre los patrones de consumo de nutrientes antioxidantes y prooxidantes con el cáncer de próstata en una población de la Ciudad de México. Participación del INCMNSZ , Francisco Rodríguez Covarrubias y cols.

Adjuvant pembrolizumab improves survival in #KidneyCancer at high recurrence risk. However, broad application may lead to overtreatment. Sarcomatoid differentiation clearly associated with poor prognosis is not used to guide adjuvant decisions. clinical-genitourinary-cancer.com/article/S1558-…

In this paper our objective was to evaluate whether histological features help refine patient selection for adjuvant immunotherapy in those at intermediate- and high-risk groups.

We analyzed data from 136 patients with localized/locally advanced #KidneyCancer treated with nephrectomy who met the KEYNOTE-564 criteria. We found that sarcomatoid differentiation was significantly associated with the risk of recurrence (HR = 2.31; 95% CI, 1.03–5.18; p = 0.042)

Thus, patients with sarcomatoid features had a 50% recurrence rate compared to 16.7% in those without these features (p = 0.007). Our findings suggest that adjuvant immunotherapy decision based on histological characteristics may optimize outcomes and avoid overtreatment.

Curso de #PCNL tips and tricks en el congreso de la Confederación Americana de Urología (CAU) en Panamá. Gracias Pablo Contreras y Guido Giusti por la oportunidad!

¡Buenas noticias en la lucha contra el cáncer de riñón en México! Este estudio encontró que cada vez más casos se detectan en etapas tempranas, lo que ha mejorado notablemente la supervivencia. Participación del INCMNSZ, Jorge Augusto Alcacio Mendoza y cols.

Orgullo #UroINCMNSZ

Felicidades a nuestro residente Carlos Alexis Orgullo #UroINCMNSZ